Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

European Journal of Nuclear Medicine and Molecular Imaging
Lisa BodeiGiovanni Paganelli

Abstract

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with (90)Y-DOTATOC and (177)Lu-DOTATATE is promising. The kidney is the critical organ and despite renal protection, function loss may become evident years later. The aim of this study was to analyse renal parameters in patients who had undergone dosimetry before PRRT. Among those in protocols at our institution, 28 patients were considered: 23 received (90)Y-DOTATOC (3.8-29.2 GBq, median 12.2) and five received (177)Lu-DOTATATE (20.7-29.2 GBq, median 23.2). Patients were followed up after therapy for creatinine and creatinine clearance loss (CCL) for 3-97 months (median 30). Renal doses and bio-effective doses (BED) were calculated (MIRD, LQ model). After (90)Y-DOTATOC toxicity on creatinine according to NCI criteria occurred in nine cases (seven grade 1, one grade 2, one grade 3), CCL at 1 year was >5% in 12 cases and >10% in eight. A 28-Gy BED threshold was observed in patients with risk factors (mainly hypertension and diabetes), while it was 40 Gy in patients without risk factors. Probably due to the low number of patients, despite the absence of severe toxicity after hyper-fractionated PRRT, clear correlations between fractionation and toxicity could n...Continue Reading

References

Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J R Cassady
Nov 7, 1999·European Journal of Nuclear Medicine·A OtteJ Muller
May 19, 2001·European Journal of Nuclear Medicine·G PaganelliF de Braud
Oct 31, 2001·European Journal of Nuclear Medicine·M CybullaA Otte
Apr 20, 2002·Seminars in Nuclear Medicine·Roelf ValkemaEric P Krenning
Apr 20, 2002·Seminars in Nuclear Medicine·Marion De JongEric P Krenning
Jan 29, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Lisa BodeiGiovanni Paganelli
Mar 14, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Stéphan WalrandStanislas Pauwels
May 20, 2004·Kidney International·Jafar Al-SaidW Charles O'Neill
May 20, 2004·European Journal of Nuclear Medicine and Molecular Imaging·Lisa BodeiGiovanni Paganelli
Mar 22, 2005·Cancer Biotherapy & Radiopharmaceuticals·Roger Dale, Alejandro Carabe-Fernandez
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dik J KwekkeboomEric P Krenning
Jun 9, 2006·The New England Journal of Medicine·Lesley A StevensAndrew S Levey
Aug 19, 2007·The American Journal of the Medical Sciences·Xin YaoKenneth Nugent
Aug 21, 2007·Lancet·Franz H MesserliEberhard Ritz

❮ Previous
Next ❯

Citations

Nov 6, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Phillip G ClaringboldJ Harvey Turner
Nov 13, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Christof SeidlReingard Senekowitsch-Schmidtke
May 10, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Giampiero GiovacchiniFlavio Forrer
Sep 6, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Lisa BodeiGiovanni Paganelli
Sep 21, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Jean-Mathieu BeauregardRodney J Hicks
Mar 6, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Lisa BodeiGiovanni Paganelli
Feb 8, 2013·European Journal of Nuclear Medicine and Molecular Imaging·L BodeiJohn J Zaknun
Feb 28, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Stefano SeveriGiovanni Paganelli
Jul 19, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Raghava KashyapRodney J Hicks
Apr 22, 2011·Annals of Hematology·Andrea PiccinSergio Cortelazzo
Sep 11, 2012·Annals of Nuclear Medicine·Sofie Van BinnebeekChristophe M Deroose
Mar 2, 2010·Cancer Biotherapy & Radiopharmaceuticals·Robert M SharkeyDavid M Goldenberg
Sep 21, 2010·Cancer Biotherapy & Radiopharmaceuticals·Jeffry A SiegelRobert M Sharkey
Sep 25, 2010·Cancer Biotherapy & Radiopharmaceuticals·Jeffry A SiegelRobert M Sharkey
Sep 21, 2010·Cancer Biotherapy & Radiopharmaceuticals·Gerald L Denardo, Daniel J Macey
Jan 6, 2011·Cancer Biotherapy & Radiopharmaceuticals·Lisa BodeiGiovanni Paganelli
Oct 26, 2011·Endocrine-related Cancer·Jaap J M TeunissenEric P Krenning
Jun 28, 2012·Theranostics·David M GoldenbergRobert M Sharkey
Sep 14, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Amir SabetSamer Ezziddin
Nov 8, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Vikas PrasadIrvin M Modlin
Nov 8, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Amir SabetSamer Ezziddin
May 9, 2014·Cancer Biotherapy & Radiopharmaceuticals·Fabio MinutoliSergio Baldari
May 17, 2014·Seminars in Nuclear Medicine·Michael Stabin, Xie George Xu
Jul 24, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Esther I van VlietDik J Kwekkeboom
Nov 17, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Edgar J RollemanMarion de Jong
Mar 29, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Sofie Van BinnebeekChristophe M Deroose
May 9, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Vikas PrasadIrvin M Modlin
Jul 30, 2014·Thoracic Surgery Clinics·Lisa BodeiGiovanni Paganelli
Jul 12, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Marta CremonesiGiovanni Paganelli
Mar 6, 2012·European Journal of Nuclear Medicine and Molecular Imaging·B L R KamD J Kwekkeboom
Jul 9, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Marleen MelisMarion de Jong
Jun 12, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Lidia StrigariGlenn Flux
Apr 26, 2014·Clinical and Translational Imaging : Reviews in Nuclear Medicine and Molecular Imaging·Sander M BisonMarion de Jong
Mar 13, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Giovanni PaganelliDino Amadori
Sep 2, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Erik VegtOtto C Boerman
Oct 3, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Lisa BodeiIrvin M Modlin
Aug 15, 2014·European Journal of Endocrinology·Wouter A van der ZwanDik J Kwekkeboom
Oct 17, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Rodney J Hicks
Feb 9, 2016·Diagnostics·Michael Ljungberg, Katarina Sjögreen Gleisner
Sep 24, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Annapaola MarinielloChiara Maria Grana
Oct 11, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Felix M MottaghyFrederik A Verburg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved